Apontis Pharma AG
XETRA:APPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Apontis Pharma AG
Free Cash Flow
Apontis Pharma AG
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Free Cash Flow
-€5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Free Cash Flow
-$113.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Free Cash Flow
€3.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
|
|
Merck KGaA
XETRA:MRK
|
Free Cash Flow
€2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Free Cash Flow
€777.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Free Cash Flow
€187.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Free Cash Flow?
Free Cash Flow
-5.2m
EUR
Based on the financial report for Dec 31, 2024, Apontis Pharma AG's Free Cash Flow amounts to -5.2m EUR.
What is Apontis Pharma AG's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-32%
Over the last year, the Free Cash Flow growth was 68%.
